Y-mAbs Therapeutics (YMAB) Director Ashu Tyagi Acquires 430,174 Shares

Y-mAbs Therapeutics (NASDAQ:YMAB) Director Ashu Tyagi purchased 430,174 shares of the business’s stock in a transaction dated Tuesday, September 25th. The stock was purchased at an average price of $16.00 per share, for a total transaction of $6,882,784.00. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Shares of Y-mAbs Therapeutics stock traded down $0.28 during trading on Thursday, reaching $24.44. The stock had a trading volume of 30,300 shares, compared to its average volume of 927,926. Y-mAbs Therapeutics has a 52 week low of $22.50 and a 52 week high of $28.03.

Y-mAbs Therapeutics Company Profile

Y-mAbs Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody therapeutic products for cancer treatment in the United States. It is developing naxitamab for the treatment of pediatric patients with relapsed or refractory, high-risk neuroblastoma, as well as other GD2 positive tumors; and omburtamab for the treatment of pediatric patients with central nervous system/leptomeningeal metastases, desmoplastic small round cell tumors, diffuse intrinsic pontine glioma, and other B7-H3 positive tumors.

Featured Article: Discover Your Risk Tolerance

Receive News & Ratings for Y-mAbs Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Y-mAbs Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply